Monopar Therapeutics Inc.

NASDAQ:MNPR

Biotechnology

Healthcare
$70.75 +2.45%

+$1.58 today

Market cap
$479.46M
Beta
1.54
P/E (TTM)
-37.6
EPS (TTM)
-$1.76
52W Low $29.18High $105.00

Volume 0.10M

Average 0.17M

MNPR Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Monopar Therapeutics Inc.NASDAQ: MNPR

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 8.54M shares rose 22.2% year over year, ahead of the -29.2% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 27.5% from the prior quarter. Over 3 fiscal years it compounded at -16.5% a year.

Context

  • Weighted avg shares (diluted) increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +22.2% holds above the trailing-twelve-month pace of -29.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
8.54M+27.5% QoQ
Last fiscal yearDec 2025
7.41M-35.5% YoY
LTMMar 2026
7.34M-29.2% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+22.2%——
1 year-35.5%——
3-year CAGR-16.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
7.41M USD
Year-over-year change
-35.5%
4-year CAGR
-12.2%

Weighted Avg Shares (Diluted) vs competitors

How MNPR compares with its peers on the latest reported figures

  • MNPR's LTM Mar 2026 weighted avg shares (diluted) of 7.34M shares is the lowest of the 11 companies compared; the peer median is 74.88M shares.
  • Its year-over-year change of -29.2% is the lowest of 11, against a peer median of +6.1%.
  • Over three fiscal years its annual growth of -16.5% compares with a peer median of +9.3%.
MNPR Competitors Peer median
Weighted Avg Shares (Diluted) for MNPR and competitors
Company Period LTM YoY 3-year CAGR
CMPXCompass Therapeutics, Inc.LTM Mar 2026161.95M +17.8%+14.5%
ADCTADC Therapeutics S.A.LTM Mar 2026138.66M +34.3%+17.6%
IMNMImmunome, Inc.LTM Sep 2026106.83M +34.8%+93.1%
IPHAInnate Pharma S.A.FY202589.42M +10.3%+3.9%
XNCRXencor, Inc.LTM Jun 202674.94M +5.1%+7.6%
ZYMEZymeworks Inc.LTM Sep 202674.82M -1.6%+4.9%
BCYCBicycle Therapeutics plcLTM Mar 202669.4M +7.1%+32.7%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
ALXOALX Oncology Holdings Inc.LTM Mar 202653.9M +2.3%+9.7%
ATNMActinium Pharmaceuticals, Inc.LTM Jun 202631.26M +0.3%+8.9%
MNPRMonopar Therapeutics Inc.LTM Mar 20267.34M -29.2%-16.5%
Peer median (excluding MNPR) 74.88M+6.1%+9.3%

Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development6.49M7.59M5.6M13.01M9.9B
Selling, General & Admin2.63M2.95M3.23M3.16M6.8B
Operating Expenses9.13M10.54M8.83M16.16M16.7M
Depreciation & Amortization00000
EBITDA(9.1M)(10.52M)(8.4M)(15.59M)(13.72M)
EBITDA Margin—————
Operating Income(9.13M)(10.54M)(8.83M)(16.16M)(16.7M)
Operating Margin—————
Interest Income24.02K21.24K429.04K404.02K2.99M
Interest Expense00000
Other Income / Expenses24.02K21.24K429.04K575.3K2.99M
Income Before Tax(9.1M)(10.52M)(8.4M)(15.59M)(13.72M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(9.1M)(10.52M)(8.4M)(15.59M)(13.72M)
Net Margin—————
EPS (Basic)(0.73)(0.83)(0.58)(1.36)(1.85)
EPS (Diluted)(0.73)(0.83)(0.58)(1.36)(1.85)
Weighted Avg Shares12.47M12.72M14.51M11.44M7.41M
Weighted Avg Shares (Diluted)12.47M12.72M14.51M11.48M7.41M

Monopar Therapeutics Inc.

NASDAQ:MNPR

Intrinsic Alpha fair value

Locked

Current Price

$70.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.